Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole
about
Pharmacokinetics and preliminary safety data of a single oral dose of bosentan, a dual endothelin receptor antagonist, in cats.Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomicsBosentan for the treatment of systemic sclerosis-associated pulmonary arterial hypertension, pulmonary fibrosis and digital ulcers.Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.Association of CYP2C9*2 with bosentan-induced liver injury.Clarithromycin substantially increases steady-state bosentan exposure in healthy volunteers.Hepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension.Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.In Silico Modeling for the Prediction of Dose and Pathway-Related Adverse Effects in Humans From In Vitro Repeated-Dose Studies.Bosentan and warfarin interaction.Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.Influence of mild liver impairment on the pharmacokinetics and metabolism of bosentan, a dual endothelin receptor antagonist.Mechanisms responsible for the altered pharmacokinetics of bosentan: analysis utilizing rats with bile duct ligation-induced liver dysfunction.Effect of ketoconazole on the pharmacokinetic profile of ambrisentan.Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects.
P2860
Q30803863-8CEB42F4-6797-4DF9-9B75-AEC3D3B63EE6Q34344390-D352D8CE-7D1A-48AA-9F68-5A61CF29EA6FQ36543145-AD2356A7-8E96-47BA-9122-436C65CB6E56Q37019838-C59AF4E5-694B-466D-B8F1-6419DAC5E935Q37325319-A5383AF0-5CD3-46AF-9955-0E665C60D918Q37492042-AB759E34-6610-4594-B77C-BC8A48B50311Q37680968-FFF77F30-1A55-448D-BF46-25495CA91E85Q37955160-6610C2DA-0F5E-46E5-A169-1C221EF3EE55Q37972127-EF922A20-5685-46A0-BF6A-8FE3EE27DE52Q38164816-C0830996-C4E4-458B-A205-E121924ED5A1Q38831372-65D201C6-3028-48F8-BCFA-186EF69E323FQ42166131-7020EAE9-CD42-402B-8B8D-7B17590D5190Q42971222-4195974F-51DB-4F78-A1CF-BBCCFEFF0D0EQ43576010-EE242CDC-8513-4481-BD17-A21C10A4C95CQ44273780-B94E418C-A8E1-43DB-9A4E-648671DA73BFQ45917004-452F4B74-9939-46B2-AB47-AE13736586B9Q46038780-36FF2FE3-4A0B-4ACD-A5EB-2B98F1BA2823Q51800322-E7FF6784-ABE5-4C7F-965D-6FCF63ADD660
P2860
Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
2002年论文
@zh
2002年论文
@zh-cn
name
Single- and multiple-dose phar ...... interaction with ketoconazole
@en
Single- and multiple-dose phar ...... interaction with ketoconazole
@nl
type
label
Single- and multiple-dose phar ...... interaction with ketoconazole
@en
Single- and multiple-dose phar ...... interaction with ketoconazole
@nl
prefLabel
Single- and multiple-dose phar ...... interaction with ketoconazole
@en
Single- and multiple-dose phar ...... interaction with ketoconazole
@nl
P2093
P2860
P1476
Single- and multiple-dose phar ...... interaction with ketoconazole
@en
P2093
Atef Halabi
Jasper Dingemanse
Paul L M van Giersbergen
P2860
P304
P356
10.1046/J.1365-2125.2002.01608.X
P407
P577
2002-06-01T00:00:00Z